Naltrexone attenuates the subjective effects of amphetamine in patients with amphetamine dependence

Neuropsychopharmacology

Volumn 33, Issue 8, 2008, Pages 1856-1863

  Jayaram Lindström, Nitya ^a,b   Konstenius, Maija ^a   Eksborg, Staffan ^b   Beck, Olof ^a   Hammarberg, Anders ^a   Franck, Johan ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Craving; Dexamphetamine; Humans; Naltrexone; Pharmacokinetics; Subjective effects

Indexed keywords

AMPHETAMINE; BENZODIAZEPINE DERIVATIVE; BENZOYLECGONINE; CANNABIS; COCAINE; DEXAMPHETAMINE; DEXTROPROPOXYPHENE; HYDROCORTISONE; NALTREXONE; NICOTINE; OPIATE; PLACEBO;

ADULT; ARTICLE; BLOOD PRESSURE MEASUREMENT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG DEPENDENCE; DRUG EFFECT; DRUG MECHANISM; HEART RATE; HUMAN; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKIN CONDUCTANCE; VISUAL ANALOG SCALE;

ADULT; AGING; AMPHETAMINE-RELATED DISORDERS; CENTRAL NERVOUS SYSTEM STIMULANTS; CROSS-OVER STUDIES; DEXTROAMPHETAMINE; DOUBLE-BLIND METHOD; ENDORPHINS; HALF-LIFE; HUMANS; HYDROCORTISONE; MALE; NALTREXONE; NARCOTIC ANTAGONISTS; PSYCHIATRIC STATUS RATING SCALES; PSYCHOLOGICAL TESTS; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 45149131619     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.npp.1301572     Document Type: Article

References (37)

1. Anton RF, Moak DH, Waid LR, Latham PK, Malcolm RJ, Dias JK (1999). Naltrexone and cognitive behavioral therapy for the treatment of outpatient alcoholics: results of a placebo-controlled trial. Am J Psychiatry 156: 1758-1764.
2. Boxenbaum HG, Riegelman S, Elashoff RM (1974). Statistical estimations in pharmacokinetics. J Pharmacokinet Biopharm 2: 123-148.
3. CAN (2001). Drogutvecklingen i Sverige, rapport 99. Rapport nr10 (1999). Folkhälsoinstitutet: Centralförbundet för Alkol och Narkotikaupplysning, Stockholm [The development of drug use in Sweden, report 2001].
4. Chick J, Anton R, Checinski K, Croop R, Drummond DC, Farmer R et al (2000). A multicentre, randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of alcohol dependence or abuse. Alcohol Alcohol 35: 587-593.
5. Cushman P Jr, Kreek MJ (1974). Methadone-maintained patients. Effect of methadone on plasma testosterone, FSH, LH, and prolactin. NY State J Med 74: 1970-1973.
6. Dunne A (1985). JANA: A new iterative polyexponential curve stripping program. Comput Methods Programs Biomed 20: 269-275.
7. Fagergren P, Smith HR, Daunais JB, Nader MA, Porrino LJ, Hurd YL (2003). Temporal upregulation of prodynorphin mRNA in the primate striatum after cocaine self-administration. Eur J Neurosci 17: 2212-2218.
8. Gorelick DA, Kim YK, Bencherif B, Boyd SJ, Nelson R, Copersino M et al (2005). Imaging brain mu-opioid receptors in abstinent cocaine users: time course and relation to cocaine craving. Biol Psychiatry 57: 573-582.
9. Hitzemann R, Curell J, Hom D (1982). Effects of naloxone on d-amphetamine- and apomorphine-induced behavior. Neuropharmacology 21: 1005-1011.
10. Hurd YL, Ungerstedt U (1989). In vivo neurochemical profile of dopamine uptake inhibitors and releasers in rat caudate-putamen. Eur J Pharmacol 166: 251-260.
11. Jaffe C, Bush KR, Straits-Troster K, Meredith C, Ronwall L, Rosenbaum G et al (2005). A comparison of methamphetamine-dependent inpatients childhood attention deficit hyperactivity disorder symptomatology. J Addict Dis 24: 133-152.
12. Jayaram-Lindstrom N, Wennberg P, Hurd YL, Franck J (2004). Effects of naltrexone on the subjective response to amphetamine in healthy volunteers. J Clin Psychopharmacol 24: 665-669.
13. Jones DN, Holtzman SG (1992). Interaction between opioid antagonists and amphetamine: evidence for mediation by central delta opioid receptors. J Pharmacol Exp Ther 262: 638-645.
14. Joyce PR, Donald RA (1987). Naloxone augments the hypothalamic-pituitary- adrenal axis response to methylphenidate in normal subjects. J Psychiatr Res 21: 297-300.
15. Kiyatkin EA, Brown PL (2003). Naloxone depresses cocaine self-administration and delays its initiation on the following day. Neuroreport 14: 251-255.
16. Kosten T, Silverman DG, Fleming J, Kosten TA, Gawin FH, Compton M et al (1992). Intravenous cocaine challenges during naltrexone maintenance: a preliminary study. Biol Psychiatry 32: 543-548.
17. Kuzmin AV, Gerrits MA, van Ree JM (1997). Naloxone inhibits the reinforcing and motivational aspects of cocaine addiction in mice. Life Sci 60: 257-264.
18. Lee MC, Wagner HN, Tanada S, Frost JJ, Bice AN, Dannals RF (1988). Duration of occupancy of opiate receptors. J Nucl Med 29: 1207-1211.
19. Martin WR, Sloan JW, Sapira JD, Jasinski DR (1971). Physiologic, subjective, and behavioural effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man. Clin Pharmacol Ther 12: 245-258.
20. Mayfield DG (1973). The effect of intravenous methamphetamine on mood. Int J Addict 8: 565-568.
21. McNair DM, Lorr M, Droppleman LF (1971). Manual for the Profile of Mood States. Educational and Industrial Testing Service: San Diego, CA.
22. Meyer MC, Straughn AB, Lo MW (1984). Bioequivalence, dose-proportionality and pharmacokinetics of naltrexone after oral administration. Clin Psychiatry 45: 15-19.
23. Naber D, Pickar D, Davis GC, Cohen RM, Jimerson DC, Elchisak MA et al (1981). Naloxone effects on beta-endorphin, cortisol, prolactin, growth hormone, HVA and MHPG in plasma of normal volunteers. Psychopharmacology (Berl) 74: 125-128.
24. O'Brien CP (2005). Anticraving medications for relapse prevention: a possible new class of psychoactive medications. Am J Psychiatry 162: 1423-1431.
25. O'Malley SS, Jaffe AJ, Chang G, Schottenfeld RS, Meyer RE, Rounsaville B (1992). Naltrexone and coping skills therapy for alcohol dependence. A controlled study. Arch Gen Psychiatry 49: 881-887.
26. Oslin DW, Pettinati HM, Volpicelli JR, Wolf AL, Kampman KM, O'Brien CP (1999). The effects of naltrexone on alcohol and cocaine use in dually addicted patients. J Subst Abuse Treat 16: 163-167.
27. Schmitz JM, Stotts AL, Rhoades HM, Grabowski J (2001). Naltrexone and relapse prevention treatment for cocaine-dependent patients. Addict Behav 26: 167-180.
28. Schmitz JM, Stotts AL, Sayre SL, DeLaune KA, Grabowski J (2004). Treatment of cocaine-alcohol dependence with naltrexone and relapse prevention therapy. Am J Addic 13: 333-341.
29. Sofuoglu M, Singha A, Kosten TR, McCance-Katz FE, Petrakis I, Oliveto A (2003). Effects of naltrexone and isradipine, alone or in combination, on cocaine responses in humans. Pharmacol Biochem Behav 75: 801-808.
30. Srisurapanont M, Jarusuraisin N, Kittirattanapaiboon P (2001). Treatment for amphetamine dependence and abuse. Cochrane Database Syst Rev CD003022.
31. Statistical Consultants Inc. (1986). PCNONLIN and NONLIN 84. Software for the statistical analysis of nonlinear models. Am Stat 40: 52.
32. Tiffany ST, Singleton E, Haertzen CA, Henningfield JE (1993). The development of a cocaine craving questionnaire. Drug Alcohol Depend 34: 19-28.
33. Trujillo KA, Belluzzi JD, Stein L (1991). Naloxone blockade of amphetamine place preference conditioning. Psychopharmacology (Berl) 104: 265-274.
34. Trujillo KA, Belluzzi JD, Stein L (1989). Naloxone suppression of self-stimulation is independent of response difficulty. Pharmacol Biochem Behav 33: 147-155.
35. Vocci F, Ling W (2005). Medications development: successes and challenges. Pharmacol Ther 108: 94-108.
36. Volpicelli JR, Alterman AI, Hayashida M, O'Brien CP (1992). Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry 49: 876-880.
37. Wang JQ, McGinty JF (1995). Alterations in striatal zif/268, preprodynorphin and preproenkephalin mRNA expression induced by repeated amphetamine administration in rats. Brain Res 673: 262-274.